Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes

Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes

Background: Elevated levels of somatostatin blunt glucagon counterregulation during hypoglycemia in type 1 diabetes (T1D) and this can be improved using somatostatin receptor 2 (SSTR2) antagonists. Hypoglycemia also occurs in late-stage type 2 diabetes (T2D), particularly when insulin therapy is ini...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Ninoschka C. D’Souza, Julian A. Aiken, Emily G. Hoffman, Sara C. Atherley, Sabrina Champsi, Nadia Aleali, Dorsa Shakeri, Maya El-Zahed, Nicky Akbarian, Mehran Nejad-Mansouri, Parinaz Z. Bavani, Richard L. Liggins, Owen Chan, Michael C. Riddell
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Frontiers Media S.A. 2024-02-01
Saila:Frontiers in Pharmacology
Gaiak:
type 2 diabetes
glucagon
hypoglycemia
counterregulation
somatostatin receptor antagonist
Sarrera elektronikoa:https://www.frontiersin.org/articles/10.3389/fphar.2024.1302015/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1302015/full

Antzeko izenburuak